HER2阳性可切除胃或胃食管结合部腺癌围手术期曲妥珠单抗联合卡培他滨和奥沙利铂的II期NEOHX试验
这项西班牙多中心开放标签II期试验评估围手术期卡培他滨、奥沙利铂联合曲妥珠单抗(XELOX-T)在HER2阳性可切除胃或胃食管结合部腺癌患者中的疗效与毒性。主要终点为18个月无病生存率,结果为71%(95%CI 53-83%)。结论认为该方案可行且有效,值得随机研究进一步验证。
要点
- 围手术期XELOX-T方案在HER2阳性可切除GA/GEJA中可行,18个月DFS为71%。
- R0切除率达90%,pCR率9.6%,主要III/IV级毒性为腹泻(33%)。
- 中位随访102个月更新显示中位OS 79.9个月,60个月OS率58%。
核心结论
- 围手术期XELOX-T在HER2阳性可切除胃或胃食管结合部腺癌患者中可行且具有抗肿瘤活性。
- 需进一步开展随机研究验证该方案。
研究设计与样本
- 西班牙多中心、开放标签、II期临床试验(NCT01130337)。
- 主要终点为18个月无病生存率;次要终点包括病理完全缓解率、R0切除率、总生存和毒性。
主要发现
- 术前三周期治疗后,14例(38%,意向治疗人群)达部分缓解,18例(50%)疾病稳定。
- 31例接受手术,其中28例(90%)实现R0切除,3例(9.6%)达病理完全缓解,3例(9.6%)死于手术并发症。
- 24例接受术后XELOX-T,其中22例完成曲妥珠单抗维持治疗。
- 主要III/IV级毒性包括腹泻(33%)、恶心呕吐(8%)。
- 中位随访24.1个月时,18个月无病生存率为71%(95%CI 53-83%);随访102个月更新显示中位总生存79.9个月,60个月总生存率58%(95%CI 40-73%)。
临床怎么用
- 对于HER2阳性可切除胃或胃食管结合部腺癌,围手术期XELOX-T可作为可行且有效的治疗选择。
- 治疗期间需关注腹泻等III/IV级毒性,并注意手术并发症风险。
局限性
- 需随机研究进一步验证疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric adenocarcinoma (GA) or gastro-oesophageal junction adenocarcinoma (GEJA). The addition of trastuzumab to chemotherapy improves outcomes in patients with HER2-positive advanced gastric cancer (GC), and we aimed to explore its role in the perioperative setting. MATERIAL AND METHODS: This Spanish, multicentre, open-label phase II trial evaluated the efficacy and toxicity of perioperative capecitabine, oxaliplatin and trastuzumab (XELOX-T) in patients with HER2-positive resectable GA or GEJA. The primary end-point was 18-months DFS; and secondary end-points included pathological complete response (pCR) rate, R0 resection rate, OS and toxicity (NCT01130337). RESULTS: Thirty-six patients were included. After three cycles of preoperative treatment, 14 patients (38% of the intention-to-treat population) had partial response and 18 (50%) had stable disease. Surgery was performed in 31 patients: 28 (90%) had R0 resection, three (9.6%) had a pCR and three (9.6%) died due to surgical complications. A total of 24 patients received post-operative XELOX-T, 22 of whom completed trastuzumab maintenance. Main grade III/IV toxicities included diarrhoea (33%), nausea and vomiting (8%). After a median follow-up of 24.1 months, 18-month DFS was 71% (95% confidence interval [CI], 53-83%); and an update after 102 months of follow-up showed a median OS of 79.9 months and a 60-month OS of 58% (95% CI, 40-73%). CONCLUSIONS: These data suggest that perioperative XELOX-T in patients with HER2-positive GA and GEJA is feasible and active. Further investigation in randomised studies is warranted.
引用
- Rivera F, Izquierdo-Manuel M, García-Alfonso P, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021. PMID: 33485079. doi:10.1016/j.ejca.2020.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。